Maximus (MMS) drew fresh attention on August 6, 2026 after releasing third quarter and nine month results and reiterating its fiscal 2026 revenue guidance toward the lower end of a projected US$5.2b to US$5.35b range.
See our latest analysis for Maximus.
At a share price of US$63.15, Maximus has seen a 12.69% 1 month share price return, while its year to date share price return is down 26.97% and the 1 year total shareholder return is down 14.18%. This suggests that recent momentum may be rebuilding after a weaker longer term trend.
If this earnings update has you considering where else capital might work hard, it could be a good moment to seek out solid balance sheet and fundamentals stocks screener (50 results)
Given Maximus has bounced in the past month but is still down sharply over the year, the real fork in the road now is simple: is this a fair entry point today, or does patience for a cheaper valuation make more sense?
Most Popular Narrative: 39.9% Undervalued
Maximus is priced at $63.15 against a most followed narrative fair value of $105, which frames the latest pullback as a valuation gap rather than a verdict on fundamentals.
The company's ongoing investments in digital, workflow automation, and AI (notably for complex health and claims processing), along with recent inorganic growth and expanded pipeline in federal and state markets, are laying the groundwork for sustainable earnings growth above the rate of revenue growth, as evidenced by recent margin performance and forward guidance.
Want to see how a modest revenue growth profile can still underpin a much higher fair value for Maximus? The narrative leans on earnings mix, margin shaping and a future profit multiple that sits well below many service peers. The interesting part is how these moving pieces are stitched together into one valuation story.
Result: Fair Value of $105 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Maximus still faces real swing factors, including potential contract volume cuts if government budgets tighten and pressure on margins if agencies adopt more in-house automation.
Find out about the key risks to this Maximus narrative.
Next Steps
The mix of optimism and concern around Maximus is clear. This is a good moment to move quickly, review the data yourself and weigh up the 5 key rewards and 1 important warning sign.
Looking for more ideas beyond Maximus?
Before you move on, give yourself the chance to spot opportunities you might otherwise overlook by using focused stock lists that narrow the market to specific strengths.
- Target resilience by scanning companies that screen well on stability and downside protection through the 79 resilient stocks with low risk scores.
- Hunt for quality at a reasonable price by checking companies that combine fundamentals with appealing valuations using the 51 high quality undervalued stocks.
- Seek dependable income by reviewing companies that aim to deliver stronger yields through the 8 dividend fortresses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com